BACKGROUND: Experience with neoadjuvant chemoradiation (CXRT) has raised questions regarding the additional benefit of surgery after locally advanced esophageal adenocarcinoma patients achieve a clinical response to CXRT. We sought to quantify the value of surgery by comparing the overall (OS) and disease-free survival (DFS) of trimodality-eligible patients treated with definitive CXRT vs. CXRT followed by esophagectomy. METHODS: We identified 143 clinical stage III esophageal adenocarcinoma patients that were eligible for trimodality therapy. All patients successfully completed neoadjuvant CXRT and were considered appropriate candidates for resection. Patients that were medically inoperable were excluded. Cox regression models were used to identify significant predictors of survival. RESULTS: Among the 143 patients eligible for surgery after completing CXRT, 114 underwent resection and 29 did not. Poorly differentiated tumors (HR = 2.041, 95% CI = 1.235-3.373) and surgical resection (HR = 0.504, 95% CI = 0.283-0.899) were the only independent predictors of OS. Patients treated with surgery had a 50 and 54 % risk reduction in overall and cancer-specific mortality, respectively. Median OS (41.2 vs. 20.3 months, p = 0.012) and DFS (21.5 vs. 11.4 months, p = 0.007) were significantly improved with the addition of surgery compared to definitive CXRT. CONCLUSIONS: Surgery provides a significant survival benefit to trimodality-eligible esophageal adenocarcinoma patients with locally advanced disease.
BACKGROUND: Experience with neoadjuvant chemoradiation (CXRT) has raised questions regarding the additional benefit of surgery after locally advanced esophageal adenocarcinomapatients achieve a clinical response to CXRT. We sought to quantify the value of surgery by comparing the overall (OS) and disease-free survival (DFS) of trimodality-eligible patients treated with definitive CXRT vs. CXRT followed by esophagectomy. METHODS: We identified 143 clinical stage III esophageal adenocarcinomapatients that were eligible for trimodality therapy. All patients successfully completed neoadjuvant CXRT and were considered appropriate candidates for resection. Patients that were medically inoperable were excluded. Cox regression models were used to identify significant predictors of survival. RESULTS: Among the 143 patients eligible for surgery after completing CXRT, 114 underwent resection and 29 did not. Poorly differentiated tumors (HR = 2.041, 95% CI = 1.235-3.373) and surgical resection (HR = 0.504, 95% CI = 0.283-0.899) were the only independent predictors of OS. Patients treated with surgery had a 50 and 54 % risk reduction in overall and cancer-specific mortality, respectively. Median OS (41.2 vs. 20.3 months, p = 0.012) and DFS (21.5 vs. 11.4 months, p = 0.007) were significantly improved with the addition of surgery compared to definitive CXRT. CONCLUSIONS: Surgery provides a significant survival benefit to trimodality-eligible esophageal adenocarcinomapatients with locally advanced disease.
Authors: Srikrishna V Patnana; Santosh B Murthy; Lianchun Xiao; Eric Rohren; Wayne L Hofstetter; Stephen G Swisher; Zhongxing Liao; Jeffrey H Lee; Manoop S Bhutani; Homer A Macapinlac; Xuemei Wang; Jaffer A Ajani Journal: Cancer Date: 2010-10-01 Impact factor: 6.860
Authors: W A Weber; K Ott; K Becker; H J Dittler; H Helmberger; N E Avril; G Meisetschläger; R Busch; J R Siewert; M Schwaiger; U Fink Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà Journal: Gut Date: 2004-07 Impact factor: 23.059
Authors: Wayne Hofstetter; Stephen G Swisher; Arlene M Correa; Kenneth Hess; Joe B Putnam; Jaffer A Ajani; Marcelo Dolormente; Rhodette Francisco; Ritsuko R Komaki; Axbal Lara; Faye Martin; David C Rice; Arcenio J Sarabia; W Roy Smythe; Ara A Vaporciyan; Garrett L Walsh; Jack A Roth Journal: Ann Surg Date: 2002-09 Impact factor: 12.969
Authors: Matthew Parsons; Shane Lloyd; Skyler Johnson; Courtney Scaife; Thomas Varghese; Robert Glasgow; Ignacio Garrido-Laguna; Randa Tao Journal: Ann Surg Oncol Date: 2020-07-09 Impact factor: 5.344
Authors: Nastaran Neishaboori; Roopma Wadhwa; Graciela M Nogueras-González; Elena Elimova; Hironori Shiozaki; Kazuki Sudo; Nikolaos Charalampakis; Adarsh Hiremath; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Mariela A Blum; Jane E Rogers; Jeana L Garris; David C Rice; Ritsuko Komaki; Stephen G Swisher; Heath D Skinner; Wayne L Hofstetter; Jaffer A Ajani Journal: Oncology Date: 2015-03-05 Impact factor: 2.935
Authors: Z Faiz; M van Putten; R H A Verhoeven; J W van Sandick; G A P Nieuwenhuijzen; M J C van der Sangen; V E P P Lemmens; B P L Wijnhoven; J T M Plukker Journal: Ann Surg Oncol Date: 2019-02-04 Impact factor: 5.344